D
Danlin Xu
Researcher at University of Chicago
Publications - 6
Citations - 1844
Danlin Xu is an academic researcher from University of Chicago. The author has contributed to research in topics: Antibody & T cell. The author has an hindex of 5, co-authored 6 publications receiving 1775 citations. Previous affiliations of Danlin Xu include Columbia University.
Papers
More filters
Journal ArticleDOI
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus
Kevan C. Herold,William Hagopian,Julie A. Auger,Ena Poumian-Ruiz,Lesley Taylor,David Donaldson,Stephen E. Gitelman,David M. Harlan,Danlin Xu,Robert Allan Zivin,Jeffrey A. Bluestone +10 more
TL;DR: Treatment with hOKT3gamma1(Ala-Ala) mitigates the deterioration in insulin production and improves metabolic control during the first year of type 1 diabetes mellitus in the majority of patients.
Journal ArticleDOI
In vitro characterization of five humanized OKT3 effector function variant antibodies.
Danlin Xu,Maria-Luisa Alegre,Sally S. Varga,Annette L. Rothermel,Alexander M. Collins,Virginia L. Pulito,Lewis S. Hanna,Kevin P. Dolan,Paul W. H. I. Parren,Jeffrey A. Bluestone,Linda K. Jolliffe,Robert Allan Zivin +11 more
TL;DR: In vitro characteristics of huOKT3gamma1(A(234), A(235)) are consistent with recent in vivo studies, in which this Ab showed greatly reduced HAMA and CRS with the retention of its ability to reverse ongoing graft rejection in man.
Journal ArticleDOI
A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
Maria-Luisa Alegre,L. J. Peterson,Danlin Xu,Husain Sattar,D R Jeyarajah,K. Kowalkowski,J. R. Thistlethwaite,R. A. Zivin,L K Jolliffe,Jeffrey A. Bluestone,Jeffrey A. Bluestone +10 more
TL;DR: An experimental model in which human splenocytes from cadaveric organ donors were inoculated into severe combined immunodeficient mice to test the activating and immunosuppressive properties of these anti-human CD3 mAbs in vivo suggests the use of an Fc variant in clinical transplantation should result in fewer side effects than observed with OKT3, while maintaining its clinical efficacy.
Journal Article
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.
Tammy O. Utset,Julie A. Auger,Donna Peace,Robert Allan Zivin,Danlin Xu,Linda K. Jolliffe,Maria-Luisa Alegre,Jeffrey A. Bluestone,Marcus R. Clark +8 more
TL;DR: Data indicate that huOKT3gamma1(ala-ala) may be useful in treating PsA, and indicates that the need for longterm global immunosuppression in autoimmune diseases may be eliminated.